Gyroscope Therapeutics Postpones Initial Public Offering
b'Gyroscope Therapeutics Holdings plc (\xe2\x80\x9cGyroscope\xe2\x80\x9d), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has postponed plans for its initial public offering.\n"In light of market conditions, we have decided to postpone our planned initial public offering," said Khurem Farooq, Chief Executive Officer.
- b'Gyroscope Therapeutics Holdings plc (\xe2\x80\x9cGyroscope\xe2\x80\x9d), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has postponed plans for its initial public offering.\n"In light of market conditions, we have decided to postpone our planned initial public offering," said Khurem Farooq, Chief Executive Officer.
- In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, as well as our earlier stage pipeline.
- "\nGyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness.
- These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.